Teva and Alvotech Collaborate to Commercialize Five Biosimilar Candidates in the US

 Teva and Alvotech Collaborate to Commercialize Five Biosimilar Candidates in the US

Teva and Alvotech Collaborate to Commercialize Five Biosimilar Candidates in the US

Shots:

  • Alvotech will lead the development, registration, and supply of the biosimilars, while Teva will be exclusively commercializing the products in the US. Alvotech will receive upfront with subsequent milestone payments over the next several years
  • The companies will share the profit from the commercialization of the biosimilars. The collaboration leverages Teva’s commercial presence and extensive infrastructure in the US along with Alvotech’s experience and state-of-the-art biologics manufacturing
  • The collaboration will improve patient access for high-quality biosimilar medicines in the US

Click here ­to­ read full press release/ article | Ref: Teva | Image: PharmaShots

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post